ProCE Banner Activity

Phase II SWOG 1318: First-line Blinatumomab Followed by POMP Maintenance in Older Patients Newly Diagnosed With Ph-Negative B-Cell ALL

Slideset Download
Conference Coverage
Frontline blinatumomab with POMP maintenance was well tolerated with no early deaths in this cohort of patients aged 65 years or older.

Released: December 03, 2018

Expiration: December 02, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology